曲美他嗪联合琥珀酸美托洛尔治疗冠心病心力衰竭的临床效果

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (0 KB) HTML (36 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the clinical effect of Trimetazidine combined with Metoprolol Succinate in the treatment of coronary heart disease (CHD)with heart failure.Methods A total of 100 CHD patients with heart failure treated in our hospital from February 2015 to March 2017 were selected,they were divided into the experimental group(n=50)and the control group (n=50)according to block randomization method.The control group received Metoprolol Succinate on the basis of basic treatment,while the experimental group received Trimetazidine and Succinate on the basis of basic treatment.The therapeutic effects,blood pressure,heart rate (HR),left ventricular ejection fraction(LVEF),left ventricular end systolic diameter(LVESD),left ventricular end diastolic diameter(LVEDD),plasma brain natriuretic peptide (BNP)and the incidence rate of adverse reactions were compared between the two groups.Results The total effective rate(96.00%)in the experimental group was higher than that in the control group(82.00%),and the difference was statistically significant(P＜0.05).The blood pressure,heart rate,LVESD and LVEDD levels in the experimental group were lower than those in the control group,and the levels of LVEF and BNP in plasma in the experimental group were higher than those in the control group,and the differences were statistically significant(P＜0.05).The total incidence of adverse reactions in the experimental group (8.00%)was lower than that in the control group(40.00%),the difference was statistically significant(P＜0.05).Conclusion Trimetazidine combined with Metoprolol Succinate can improve the therapeutic effect and cardiac function of CHD patients with heart failure,and it is safe to use Trimetazidine and Metoprolol Succinate.

Key words： Trimetazidine Metoprolol Succinate Coronary heart disease Heart failure

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHU Ling-hua
	ZHU Ming-zhen

Cite this article:

ZHU Ling-hua,ZHU Ming-zhen. Clinical efficacy of Trimetazidine combined with Metoprolol Succinate in the treatment of coronary heart disease with heart failure[J]. 中国当代医药, 2018, 25(29): 43-45.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2018/V25/I29/43

[1]	黎洁雯.美托洛尔联合曲美他嗪对冠心病心力衰竭病人心脏功能的影响[J].中西医结合心脑血管病杂志，2016，14（21）：2540-2541.
[2]	赵秀芳.美托洛尔联合曲美他嗪治疗冠心病心力衰竭的临床疗效[J].中外医疗，2016，35（28）：136-138，141.
[3]	袁伟，张玮，李小荣，等.曲美他嗪改善冠状动脉支架置入术后患者生活质量的临床研究[J].实用心电学杂志，2016，25（5）：346-348.
[4]	高连君.心力衰竭与室性心律失常[J].实用心电学杂志，2018，27（4）：238-240.
[5]	王堃.浅析曲美他嗪联合琥珀酸美托洛尔治疗冠心病心力衰竭患者的临床效果及安全性[J].健康前沿，2018，27（2）：137，140.
[6]	胡明艳.观察曲美他嗪联合琥珀酸美托洛尔治疗冠心病心力衰竭患者的临床效果[J].中西医结合心血管病电子杂志，2018，6（3）：82-83.
[7]	姜春玲.美托洛尔联合曲美他嗪治疗冠心病心力衰竭的疗效及安全性分析[J].陕西医学杂志，2016，45（8）：1064-1065.
[8]	王一丹，王婷婷.盐酸曲美他嗪联合美托洛尔治疗缺血性心肌病心力衰竭的临床疗效[J].中国老年学杂志，2018，38（6）：1333-1335.
[9]	姚朝阳.麝香保心丸联合美托洛尔及曲美他嗪治疗冠心病心力衰竭的临床研究[J].中西医结合心脑血管病杂志，2016，14（6）：615-617.
[10]	杨会萍，任骞.美托洛尔联合曲美他嗪对冠心病心力衰竭患者炎性反应、T细胞亚群及心功能的影响研究[J].实用心脑肺血管病杂志，2016，24（8）：20-23.
[11]	孙小军，卢京.美托洛尔联合曲美他嗪治疗冠心病心力衰竭的临床疗效观察[J].中国医院用药评价与分析，2015，15（3）：312-314.
[12]	李平，李佑美.曲美他嗪联合美托洛尔治疗冠心病心力衰竭对血浆BNP影响及疗效观察[J].海南医学院学报，2016，22（2）：126-128.
[13]	顾丽萍，胡菁，严蜀华，等.美托洛尔与曲美他嗪治疗老年冠心病心力衰竭的疗效及对患者心功能、心肌重塑和炎症因子的影响[J].中国老年学杂志，2017，37（1）：89-91.
[14]	施中平，戴海岳.美托洛尔联合曲美他嗪治疗冠心病心力衰竭患者临床疗效观察[J].中国生化药物杂志，2017，37（9）：278-279.
[15]	李堪董，赵圣吉，史丽，等.曲美他嗪联合美托洛尔治疗老年冠心病合并心力衰竭的临床研究[J].中国临床药理学杂志，2018，34（5）：507-510.